Mesoblast's positive Revascor data could expand market for heart stem cell therapy
This article was originally published in Clinica
Executive Summary
Mesoblast is set to press on with Phase IIb trials of Revascor, its cardiovascular stem cell therapy, following positive Phase IIa results.